Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
Authors
Halle-Smith, J. M.Hall, L.
Daamen, L. A.
Hodson, J.
Pande, R.
Young, A.
Jamieson, N. B.
Lamarca, Angela
van Santvoort, H. C.
Molenaar, I. Q.
Valle, Juan W
Roberts, K. J.
Affiliation
Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom.Issue Date
2021
Metadata
Show full item recordAbstract
Background: The value of routine surveillance after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear, and expert guidelines offer conflicting recommendations. This study is a systematic review of evidence for surveillance programs. Methods: A systematic review of studies evaluating different surveillance methods was undertaken. A meta-analysis was performed for those studies reporting rates of asymptomatic recurrence, treatment of recurrence and overall survival, according to different surveillance methods. Results: Ten studies were included in the literature review, with five studies appropriate for meta-analysis (1596 patients). Patients within active surveillance programs were more likely to have recurrence detected at an asymptomatic stage (Pooled Rate: 49.3% vs. 19.1%, p = 0.043). Within studies reporting these outcomes, patients with asymptomatic recurrence were more likely to receive treatment for recurrence (Odds Ratio 3.49; 95% CI: 1.73-7.07; p < 0.001) and had longer overall survival (Mean Difference: 9.5 months; 95% CI: 4.1-14.8; p < 0.001) than those with symptoms at time of recurrence. Discussion: Routine surveillance after surgery for PDAC appears to detect more patients at an asymptomatic stage. Data from these non-randomised trials also suggest that treatment rates and survival may be superior in patients were recurrence is detected when asymptomatic. As such, these data suggest that routine surveillance may improve patient outcomes, although an appropriately conducted trial would be required to address concerns that various sources of bias may be affecting these results.Citation
Halle-Smith JM, Hall L, Daamen LA, Hodson J, Pande R, Young A, et al. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology. 2021 May.Journal
European Journal of Surgical OncologyDOI
10.1016/j.ejso.2021.04.031PubMed ID
34034941Additional Links
https://dx.doi.org/10.1016/j.ejso.2021.04.031Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejso.2021.04.031
Scopus Count
Collections
Related articles
- Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
- Authors: Daamen LA, van Goor IWJM, Groot VP, Andel PCM, Brosens LAA, Busch OR, Cirkel GA, Mohammad NH, Heerkens HD, de Hingh IHJT, Hoogwater F, van Laarhoven HWM, Los M, Meijer GJ, de Meijer VE, Pande R, Roberts KJ, Stoker J, Stommel MWJ, van Tienhoven G, Verdonk RC, Verkooijen HM, Wessels FJ, Wilmink JW, Besselink MG, van Santvoort HC, Intven MPW, Molenaar IQ, Dutch Pancreatic Cancer Group
- Issue date: 2024 Jun 20
- CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
- Authors: Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME
- Issue date: 2018 Nov
- Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
- Authors: Hosokawa Y, Nagakawa Y, Sahara Y, Takishita C, Katsumata K, Tsuchida A
- Issue date: 2017
- Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
- Authors: Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD
- Issue date: 2020 Nov
- Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
- Authors: Nakagawa K, Akahori T, Nishiwada S, Nagai M, Nakamura K, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Ikeda N, Sho M
- Issue date: 2018 Sep